Xeris Pharmaceuticals | XERS - 销售收入



金融业
股票价格
USD
资产
USD 411.91M
现金及等价物
USD 121.75M
销售成本
USD 10.57M
流动资产
USD 274.76M
流动负债
USD 189.57M
债务
USD 258.55M
EBIT
USD 9.12M
EBITDA
USD 12.33M
员工
377
EPS每股收益
USD 0.01
股本和储备
USD -9.73M
销售毛利
USD 72.55M
债务利息支出
USD 6.88M
利息收入
USD 1.2M
贷款资金
USD 188.81M
市值
USD 1.08B
净收入
USD 2.23M
营业费用
USD 75.21M
营业利润
USD 7.92M
普通股股本
USD 172.56M
PE价格收益
76.05
税前利润
USD 2.23M
销售收入
USD 83.13M
销售和管理费用
USD 53.14M
股票
USD 80.93M
贸易债权人
USD 9.34M
应收帐款人
USD 56.3M


销售 更改 日
Celltrion KRW 1.24T 90B 2026-06
Cspc Pharmaceutical CNY 6.47B 355.1M 2026-03
Deva Holding AS TRY 2.32B 418.58M 2023-09
Dianthus Therapeutics USD 463K 179K 2026-03
Divis Laboratories Ltd INR 27.58B 730M 2026-06
Eli Lilly USD 22.97B 3.17B 2026-06
Kangmei Pharma CNY 1.08B 288.27M 2026-03
Knight Therapeutics CAD 133.11M 11.56M 2025-12
Laboratorios Farma EUR 448.66M 67.82M 2023-12
Medical Developments International AUD 21.57M 12.04M 2025-12
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Neuren Pharmaceuticals AUD 42.24M 28.1M 2025-12
Organigram Holdings CAD 59.79M 3.74M 2026-03
Pacira USD 192.4M 15.4M 2026-06
Perrigo USD 1.02B 51M 2026-06
Pharma Mar EUR 50M 7.1M 2026-06
Qiagen NV USD 463.12M 43.9M 2026-06
Sartorius EUR 911.8M 12.7M 2026-06
Sino Biopharmaceutical CNY 19.44B 5.18B 2026-06
Supernus Pharmaceuticals USD 219.1M 11.39M 2026-06
Tilray USD 217.51M 74.75M 2025-12
Zealand Pharma A/S 34M 34.92M 2026-03
Zhangzhou Pientzehuang Pharmaceutical CNY 1.83B 887.63M 2026-06